MARKET

FBIO

FBIO

Fortress Biotech Inc
NASDAQ
1.750
-0.060
-3.31%
Closed 17:55 04/22 EDT
OPEN
1.730
PREV CLOSE
1.750
HIGH
1.780
LOW
1.730
VOLUME
151.08K
TURNOVER
0
52 WEEK HIGH
12.00
52 WEEK LOW
1.240
MARKET CAP
33.66M
P/E (TTM)
-0.2067
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FBIO last week (0415-0419)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 5d ago
Weekly Report: what happened at FBIO last week (0408-0412)?
Weekly Report · 04/15 09:38
Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments
TipRanks · 04/09 10:17
Weekly Report: what happened at FBIO last week (0401-0405)?
Weekly Report · 04/08 09:40
Weekly Report: what happened at FBIO last week (0325-0329)?
Weekly Report · 04/01 09:40
Fortress Biotech Q4 EPS $(0.53) Beats $(1.97) Estimate, Sales $19.95M Beat $14.89M Estimate
Fortress Biotech reported quarterly losses of $0.53 per share. The company reported quarterly sales of $19.95 million which beat the analyst consensus estimate of $14.89 million. Fortress Biotech also reported a 55.83 percent increase in sales from the same period last year.
Benzinga · 03/29 03:33
Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary
Fortress Biotech Inc reports results for the quarter ended in December. Revenue rose 21.6% to $19.95 million from a year ago. The company reported a quarterly adjusted loss of 53 cents per share. The mean expectation of five analysts was for a loss of $1.97.
Reuters · 03/28 23:25
More
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Webull offers Fortress Biotech Inc stock information, including NASDAQ: FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.